
Sign up to save your podcasts
Or


Recorded on 02/04/22
Cowen Analyst Yaron Werber speaks with Jean-Francois Formela, Partner at Atlas Venture and Otello Stampacchia, Founder of Omega Funds about investing in and building companies from the ground up, particularly in light of the unprecedented pace of innovation in biotech. Science prevails when it comes to investing in early-stage biotechs, but many key strategic and financing decisions need to be made along the way, especially as relating to selling the company or going it alone.
For Disclosures, click here bit.ly/3cPHkNW
https://go.td.com/PodcastDisclosure
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By TD Securities, TD Cowen4.8
3636 ratings
Recorded on 02/04/22
Cowen Analyst Yaron Werber speaks with Jean-Francois Formela, Partner at Atlas Venture and Otello Stampacchia, Founder of Omega Funds about investing in and building companies from the ground up, particularly in light of the unprecedented pace of innovation in biotech. Science prevails when it comes to investing in early-stage biotechs, but many key strategic and financing decisions need to be made along the way, especially as relating to selling the company or going it alone.
For Disclosures, click here bit.ly/3cPHkNW
https://go.td.com/PodcastDisclosure
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

3,067 Listeners

4,654 Listeners

1,929 Listeners

9,526 Listeners

940 Listeners

125 Listeners

322 Listeners

1,037 Listeners

291 Listeners

1,296 Listeners

9,938 Listeners

33 Listeners

517 Listeners

1,423 Listeners

44 Listeners